Drug-induced liver injury: What was new in 2008?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 8, 2009, Pages 843-860

  Liss, Gordon ^b   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

DILI; Dilin network; Drug induced liver injury; Hepatotoxicity

Indexed keywords

ABACAVIR; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BROMFENAC; CENTRAL NERVOUS SYSTEM AGENTS; COTRIMOXAZOLE; DARUNAVIR; ERLOTINIB; ETANERCEPT; FLUCLOXACILLIN; HERBACEOUS AGENT; ISONIAZID; KAVA; METHYLPREDNISOLONE; NATALIZUMAB; NITROFURANTOIN; OLANZAPINE; PARACETAMOL; PEMOLINE; QUETIAPINE; RITONAVIR; SORAFENIB; SUNITINIB; TELITHROMYCIN; TRASTUZUMAB; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; XIMELAGATRAN;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; GENETIC PREDISPOSITION; GENETIC SCREENING; HEPATORENAL SYNDROME; HERBAL MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JAUNDICE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PREVALENCE; RELIABILITY; REVIEW; RISK FACTOR; SIDE EFFECT; STOMATITIS;

ALANINE TRANSAMINASE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS, TOXIC; HUMANS; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 68149157299     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903018904     Document Type: Review

References (181)

1. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd edition. Philadelphia PA: Lippincott Williams and Wilkins, 1999 • The seminal source on all aspects of DILI.
2. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739 • An up-to-date review of various injury patterns and mechanisms of DILI.
3. Lewis JH, Kleiner DE. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween's pathology of the liver, 5th edition. Amsterdam: Churchill Livingstone Elsevier; 2006. p. 649-759 • A comprehensive review of the clinical and pathologic aspects of all classes of hepatotoxic drugs and chemicals.
4. Lewis JH. Liver disease caused by anesthetics, toxins, and herbal preparations. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/ management, 8th edition. Philadelphia: Saunders Elsevier, 2006. p. 1853-1868
5. Carey EJ, Vargas HE, Douglas DD, et al. Inpatient admissions for drug-induced liver injury: results from a single center. J Dig Dis Sci 2008;53(7):1977-1982
6. Galan MV, Potts JA, Siverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-67
7. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-143 (Pubitemid 40674746)
8. De Valle MB, Av Klinteberg V, Alem N, et al. Drug induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-1195 (Pubitemid 44427506)
9. Vuppalanchi R, Liangpunsakul S, Chalasani N, et al. Etiology of new onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007;102:558-562
10. Hussaini SH, O'Brien CS, Despott EJ, et al. Antiobiotic therapy: a major cause of drug-induced jaundice in southwest Englang. Eur J Gastroenterol Hepatol 2007;19:15-20
11. Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc 2007;99:1381-1385 (Pubitemid 350308720)
12. Andrade RJ, Lucena MI, Fernandez C, et al. Drug induced injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129:512-521 • Summarizes the results of DILI in a large Spanish registry.
13. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005;42:481-489 • Summarizes the results of DILI in a large Swedish registry. (Pubitemid 41061102)
14. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934 • The first formal publication describing patients entered into the US DILIN Network registry; antimicrobials and anticonvulsants lead the list of non-acetaminophen hepatotoxins.
15. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505 • A comprehensive review of the components of RUCAM and other causality assessment methods for DILI.
16. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310 (Pubitemid 32016915)
17. Rochling FA, Zetterman RK. Do hepatotoxicity registries have a role in health care? Gastroenterology 2008;135:1847-1850
18. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-1435 (Pubitemid 350045603)
19. FDA Safety Alerts for Human Medical Products accessed at http://www.fda.gov/ medwatch/safety.htm • An important source of up-to-date safety information on all classes of medications and supplements.
20. Srinivasan S, Parsa V, Liu CY, et al. Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008;42:1497-1501
21. Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008;103:2162-2163
22. Shpaner A, Li W, Ankoma-Sey V, et al. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008;20:1106-1109
23. Farah M, Al Rashidi A, Owen DA, et al. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008;35:349-351 (Pubitemid 351281159)
24. Leak AM, Rincon-Aznar B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 2008;35:2286-2287
25. Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 2008;28:1066-1070
26. Watkins PB. Drug-induced liver injury network. Am J Gastroenterol 2008;103:1574-1575
27. Guéant JL, Guéant-Rodriguez RM, Gastin IA, et al. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Curr Pharm Des 2008;14:2770-2777
28. Ingelman-Sundberg M. Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions. N Engl J Med 2008;358:637-639 (Pubitemid 351214293)
29. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579 • The first large scale program to identify patients at risk of abacavir hypersensitivity.
30. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-2033
31. Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008;22:1673-1675
32. Colombo S, Rauch A, Rotger M, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864-867
33. Day C. European Hepatology Networks: UK. Drug-induced liver injury: Standardization of nomenclature and causality assessment. NIH workshop Dec 1-2, 2008. Lister Hill Auditorium: Bethesda, MD. p. 12
34. Andrews E, Daly AK. Flucloxacillin induced liver injury. Toxicology 2008;254:158-163
35. Ozer J, Ratner M, Shaw M. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194-205
36. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637-639 • An authoritative review on the potential biomarkers for DILI as well as other adverse drug reactions. (Pubitemid 351214293)
37. Pachkoria K, Lucena MI, Molokhia M, et al. Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2007;2:97-112 (Pubitemid 46812950)
38. Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008;9:538-545
39. Lucena MI, Andrade RJ, Martínez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-596
40. Miller TJ, Knapton A, Adeyemo O, et al. Cytochrome c: a non-invasive biomarker of drug-induced liver injury. J Appl Toxicol 2008;28:815-828
41. Xu JJ, Henstock PV, Dunn MC, et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105
42. Thum T, Borlak J. Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes. Arch Toxicol 2008;82:89-101 (Pubitemid 351187672)
43. Barros SA, Martin RB. Predictive toxicogenomics in preclinical discovery. Methods Mol Biol 2008;460:89-112
44. Antoine DJ, Williams DP, Park BK. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol 2008;4:1415-1427
45. Tuschl G, Lauer B, Mueller SO. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin Drug Metab Toxicol 2008;4:855-870
46. Boelsterli UA, Hsiao CJ. The heterozygous Sod2(+/-) mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 2008;13:982-988
47. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-2009 • These investigators have challenged the notion that not all idiosyncratic DILI is unrelated to dose. Drugs given in daily doses less than 50 mg appear rarely to be hepatotoxic. (Pubitemid 351945567)
48. Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-1815
49. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007;47:513-539 (Pubitemid 46272137)
50. Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008;28:1021-1041 • The old adage that most drugs can be given safely to patients with liver disease is upheld in this review of the topic. Underlying viral hepatitis, however, may pose a threat of DILI with HAART and TB drugs, in particular.
51. Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008;103:2231-2238
52. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-1463 • The first prospective controlled trial showing hepatic safety of a statin in patients with chronic liver disease (mostly NAFLD and HCV). (Pubitemid 350155527)
53. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-65 (Pubitemid 40250595)
54. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292 (Pubitemid 38552793)
55. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10 • Newer upper limit of normal for ALT is reduced to 30 IU for men and 19 IU for women. (Pubitemid 34705370)
56. García-Romero D, Anastassiou J, Hart G, et al. High prevalence of abnormal alanine and aspartate aminotransferases in a "worried-well" population in the United Kingdom: rationale for a liver screening program? Hepatology 2008;48:1729-1730
57. Halegoua-De Marzio D, Navarro VJ. Drug-induced hepatotoxicity in humans. Curr Opin Drug Discov Devel 2008;11:53-59
58. FDA Draft Guidance for Industry October 2007. Drug-Induced Liver Injury: Premarketing Clinical Evaluation accessed by http://www.fda.gov/cder/ Guidance/7507dft.pdf • An excellent review of the definitions and significance of biochemical and clinical signals of hepatotoxicity during drug development.
59. European Medicines Agency. Non-clinical guideline on drug-induced hepatotoxicity; European Medicines Agency, DRAFT 2008. Accessed at www.emea.europa.eu
60. García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-789
61. Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther 2008;46:327-339 • The first attempt to utilize the RUCAM scoring system to identify the hepatotoxic potential of a new drug in clinical development. (Pubitemid 352005926)
62. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-83 • The DILIN investigators still consider 'expert judgment' to be superior to RUCAM in assessing causality.
63. Lucena MI, García-Cortés M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008;22:141-158
64. Etwel FA, Rieder MJ, Bend JR, et al. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Saf 2008;31:169-180 (Pubitemid 351158527)
65. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008;359:285-292 • A comprehensive review of the pathophysiology and treatment options for acetaminophen overdose.
66. Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008;28:175-187 (Pubitemid 351632957)
67. Lee WM, Squires RH Jr, Nyberg SL, et al. Summary of a workshop. Hepatology 2008;47:1401-1415
68. Murray KF, Hadzic N, Wirth S, et al. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008;47:395-405 • The causes of acute DILI causing fulminant hepatic failure in children differs from that seen in adults; "indeterminant" causes lead the list with acetaminophen being only 15% of cases (less than one-third of cases seen in adults).
69. Pearce B, Grant IS. Acute liver failure following therapeutic paracetamol administration in patients with muscular dystrophies. Anaesthesia 2008;63:89-91 (Pubitemid 350233217)
70. Smith SW, Howland MA, Hoffman RS, et al. Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Ann Pharmacother 2008;42:1333-1339
71. Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, et al. The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology 2008;243:261-270
72. Terneus MV, Brown JM, Carpenter AB, et al. Comparison of S-adenosyl-L-methionine (SAMe) and N-acetylcysteine (NAC) protective effects on hepatic damage when administered after acetaminophen overdose. Toxicology 2008;244:25-34
73. Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008;84:1410-1421 (Pubitemid 352774476)
74. Bajt ML, Yan HM, Farhood A, et al. Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci 2008;104:419-427 (Pubitemid 352038264)
75. Donthamsetty S, Bhave VS, Mitra MS, et al. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol Appl Pharmacol 2008;230:327-337
76. Aleksunes LM, Slitt AL, Maher JM, et al, Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol 2008;226:74-83
77. Aleksunes LM, Campion SN, Goedken MJ, et al. Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci 2008;104:261-273
78. Campion SN, Johnson R, Aleksunes LM, et al. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 2008;295:G294-304
79. Yalçin S, Bilgili A, Onbasilar I, et al. Synergistic action of sodium selenite and N-acetylcysteine in acetaminophen induced liver damage. Hum Exp Toxicol 2008;27:425-429
80. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008;101:523-530
81. Ding GK, Buckley NA. Evidence and consequences of spectrum bias in studies of criteria for liver transplant in paracetamol hepatotoxicity. QJM 2008;101:723-729
82. Ali FM, Boyer EW, Bird SB, et al. Estimated risk of hepatotoxicity after an acute acetaminophen overdose in alcoholics. Alcohol 2008;42:213-218
83. Bartels S, Sivilotti M, Crosby D, et al. Are recommended doses of APAP hepatotoxic for recently abstienent alcoholics? A randomized trial. Clin Toxicol 2008;46:243-249
84. Waring WS, Robinson OD, Stephen AF, et al. Does the patient history predict hepatotoxicity after acute paracetamol overdose? QJM 2008;101:121-125
85. Waring WS, Stephen AF, Malkowska AM, et al. Acute ethanol coingestion confers a lower risk of hepatotoxicity after deliberate acetaminophen overdose. Acad Emerg Med 2008;15:54-58
86. Myers RP, Shaheen AA, Li B, et al. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 2008;6:918-925
87. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008;9:1092-1101
88. Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008;9:1181-1190
89. Domènech E, Mañosa M, Navarro M, et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008;42:395-399
90. Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008;35:1454-1457 (Pubitemid 352000803)
91. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572-579
92. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in IBD: the role for adding allopurinol. Expert Opin Drug Saf 2008;7(5):607-616
93. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:734-741
94. Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf 2008;31:325-334
95. Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe- induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008;28:1188-1193
96. Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24:2953-2966
97. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197:S279-93 • A practical approach to identifying and managing suspected HAART-associated DILI.
98. Brück S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008;13:343-348
99. Shah T, Lampiris H, Vu M, et al. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual. J Infect Dis 2008;197:932-933
100. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-1485
101. Medrano J, Barreiro P, Tuma P, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev 2008;10:110-115
102. Chan-Tack KM, Struble KA, Birnkrant DB. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDS 2008;22:843-850
103. Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol 2008;20:1194-1204 • A thorough review of HAART hepatotoxicity.
104. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174 :935-952 • The latest guidelines on monitoring for DILI during anti-tuberculosis therapy.
105. Liu Q, Garner P, Wang Y, et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008;8:365
106. Marzuki OA, Fauzi AR, Ayoub S, et al. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008;49:688-693
107. Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008;177:1391-1396
108. Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008;12:994-1002
109. Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 2008;9:311-321
110. Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673-681
111. Leiro V, Fernández-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008;28:835-839 (Pubitemid 351818646)
112. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-697
113. Shen C, Meng Q, Zhang G, et al. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol 2008;153:784-791 (Pubitemid 351271758)
114. Lobato MN, Jereb JA, Starke JR. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics 2008;121:e1732-3
115. Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond) 2008;5:18
116. Fontana RJ, Shakil AO, Greenson JK, et al. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005;50:1785-1790 (Pubitemid 41413891)
117. Devereaux BM, Crawford DH, Purcell P, et al. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995;49:81-85
118. Chen Y, Guo JJ, Healy DP, et al. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother 2008;42:1791-1796
119. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-257 • Discusses the clinical features of DILI related to this new antibiotic.
120. Bolesta S, Roslund BP. Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review. Am J Health Syst Pharm 2008;65:37-41
121. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-179 (Pubitemid 36135187)
122. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005;41:237-246 (Pubitemid 40165367)
123. Snow KL, Moseley RH. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci 2007;80:732-740
124. Lee YH, Chung MC, Lin Q, et al. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol Appl Pharmacol 2008;231:43-51
125. Julie NL, Julie IM, Kende AI, et al. Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone. Diabetologia 2008;51:2108-2116
126. Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2008;23:366-373 (Pubitemid 351342073)
127. Herrera S, Bruguera M. Hepatotoxicity induced by herbs and medicines used to induce weight loss. Gastroenterol Hepatol 2008;31:447-453
128. Manso G, López-Rivas L, Duque JM, et al. Spanish reports of hepatotoxicity associated with Herbalife products. J Hepatol 2008;49:289-90-91
129. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901-910
130. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci 2005;50:1807-1812
131. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008;31:469-484 • A comprehensive review of the hepatic injury associated with green tea from a number of different worldwide sources.
132. Gloro R, Hourmand-Ollivier I, Mosquet B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005;17:1135-1137 (Pubitemid 41424011)
133. Molinari M, Watt KD, Kruszyna T. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006;12:1892-1895 (Pubitemid 44911818)
134. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008;66:758-766
135. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008;20:1182-1193
136. Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. N Z Med J 2008;121:90-98
137. García-Cortés M, Lucena MI, Andrade RJ, et al. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother 2004;38:1540-1541
138. Lee CH, Wang JD, Chen PC. Case-crossover study of hospitalization for acute hepatitis in Chinese herb users. J Gastroenterol Hepatol 2008;23:1549-1555
139. Foti RS, Dickmann LJ, Davis JA, et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008;38:264-280
140. Available from: www.cfsan.fda. gov/∼dms/ds-warn.html
141. Lüde S, Török M, Dieterle S, et al. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 2008;15:120-131 (Pubitemid 350297905)
142. Available from: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5147a1.htm
143. Grillo MP, Hua F, March KL, et al. Gamma-glutamyltranspeptidase-mediated degradation of diclofenac-S-acyl-glutathione in vitro and in vivo in rat. Chem Res Toxicol 2008;21:1933-1938
144. Grillo MP, Ma J, Teffera Y, et al. A novel bioactivation pathway for 2-[2-(2,6-dichlorophenyl)aminophenyl] ethanoic acid (diclofenac) initiated by cytochrome P450-mediated oxidative decarboxylation. Drug Metab Dispos 2008;36:1740-1744
145. Walker SL, Kennedy F, Niamh N, et al. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf 2008;17:1108-1112
146. Abraham C, Hart J, Locke SM, et al. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2008;5:172-176 (Pubitemid 351344543)
147. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008;118:281-290
148. Moeller KE, Wei L, Jewell AD, et al. Acute hepatotoxicity associated with lamotrigine. Am J Psychiatry 2008;165:539-540
149. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31:345-354
150. McFarland R, Hudson G, Taylor RW, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008;93:151-153 (Pubitemid 351204758)
151. Reuben A. Hy's Law. Hepatology 2004;39:574-8 • Provides the historical basis for 'Hy's Law', which predicted an ominious prognosis for drug-induced hepatocellular jaundice.
152. Lewis JH. 'Hy's Law, the Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidmiol Drug Saf 2006;15:221-229 • Reviews the various biochemical signals of drug-induced hepatotoxicity used in drug development, and analyzes them in the context of current approaches to making benefit-risk decisions.
153. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidmiol Drug Saf 2006;15:241-3 • This comments further on the meaning of 'Hy's Law' from the FDA perspective.
154. Abusin S, Johnson S. Sulfamethoxazole/ Trimethoprim induced liver failure: a case report. Cases J 2008;1:44
155. Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol 2008;20:796-799
156. Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J Gen Intern Med 2008;23:1914-1916
157. Whitt KN, Ward SC, Deniz K, et al. Cholestatic liver injury associated with whey protein and creatine supplements. Semin Liver Dis 2008;28:226-231 (Pubitemid 351632962)
158. Soyuncu S, Cete Y, Nokay AE. Portal vein thrombosis related to Cassia angustifolia. Clin Toxicol (Phila) 2008;46:774-777
159. Cohen DL, Del Toro Y. A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 2008;42:961-962
160. Poon WT, Chau TL, Lai CK, et al. Hepatitis induced by Teucrium viscidum. Clin Toxicol (Phila) 2008;46:819-822
161. Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008;14:6999-7004
162. Stadlbauer V, Weiss S, Payer F, et al. Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with morinda citrifolia (noni). Am J Gastroenterol 2008;103:2406-2407
163. Shah NL, Zacharias I, Khettry U, et al. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol 2008;6:255-258
164. Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31:643-665 Review
165. Veltkamp SA, Pluim D, van Tellingen O, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 2008;36:1606-1615
166. Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008;51 Suppl 1:19-24 (Pubitemid 351678032)
167. O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy 2008;28:1071-1075
168. Castro Beza I, Sánchez Ruiz J, Peracaula Espino FJ, et al. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol 2008;10:591-592
169. Chan AL, Hsieh HJ, Hsieh YA, et al. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther 2008;46:96-101 (Pubitemid 351233795)
170. Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol 2008;6:228-236
171. Arkun A, Van Deusen SK, Grau T, et al. Hepatic Dysfunction and Neurotoxicity in a Patient Receiving Long-Term Low-Dose Amiodarone Therapy. J Emerg Med 2008 (Epub ahead of print)
172. Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008;9:48 (Pubitemid 351581169)
173. Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Reports 2008;2:140 (Pubitemid 351837201)
174. Wiper A, Schmitt M, Roberts DH. Clopidogrel-induced hepatotoxicity. J Postgrad Med 2008;54:152
175. Wolfhagen FH, Vermeulen HG, de Man RA, et al. Initially obscure hepatotoxicity attributed to sildenafil. Eur J Gastroenterol Hepatol 2008;20:710-712
176. Alotaibi WM. Severe hepatic dysfunction after sevoflurane exposure. Saudi Med J 2008;29:1344-1346
177. Lewandowski MJ, Chapman SA. Ondansetron-induced aminotransferase level elevation: case report and review of the literature. Pharmacotherapy 2008;28:1542-1546
178. Müller J, Kralovánszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res 2008;28:3051-3054
179. Thia TJ, Tan HH, Chuah TH, et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 2008;49:e86-9
180. Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent recativation. Chemotherapy 2009;55:69-75 • The risk of hepatitis B reactivation is high among patients receiving chemotherapy.
181. El-Naggar MH, Helmy A, Moawad M, et al. Late-onset rosiglitazone- associated acute liver failure in a patient with Hodgkin's lymphoma. Ann Pharmacother 2008;42:713-718 (Pubitemid 351619944)